Itacitinib monotherapy for GVHD, the role of ERG in EVI1-driven AML, and germline DDX41 mutations in myeloid neoplasms

episode

Blood Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Busting Brain Myths: TikTok's Viral Neuroscientist 11 min · 24 Sep 2026 · Today with David McCullagh

We Investigated the Christian "Scam" Fronted by Tim Tebow 1h 17m · 24 Sep 2026 · Pablo Torre Finds Out

Trump threatens Iran in fiery UN speech. What's next? 14 min · 24 Sep 2026 · The Excerpt

Dolly Parton library at risk of closure 5 min · 24 Sep 2026 · Today with David McCullagh

Have schoolchildren forgotten how to handwrite? 16 min · 24 Sep 2026 · Today with David McCullagh

Iran Addresses the World & Inside CA’s Welfare Scandal | 9.24.26 19 min · 24 Sep 2026 · Morning Wire

Report any issue

Source

Recorded02 Feb 2023

Publisherfeeds.transistor.fm ↗

Handlerec:11742045

Show notes

In this week's episode, we’ll discuss the safety and efficacy of itacitinib monotherapy in low-risk acute GVHD, learn how ERG was discovered to be a key transcriptional target in EVI1-driven AML, and define a unique subtype of myeloid neoplasms characterized by germline DDX41 mutations.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in